Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17474582 | 1.00 | MAPT (0.54) | MAPTPKMSLC6A4SLC6A3SLC6A2 | |
| SCHEMBL2232983 | 0.89 | MAPT (0.51) | MAPTPKMSLC6A4SLC6A3SLC6A2 | |
| SCHEMBL2232991 | 0.89 | MAPT (0.51) | MAPTPKMSLC6A4SLC6A3SLC6A2 | |
| SCHEMBL17485235 | 0.84 | MAPT (0.55) | MAPTPKMSLC6A4SLC6A3SLC6A2 | |
| SCHEMBL17486605 | 0.84 | MAPT (0.63) | MAPTPKMSLC6A3ALDH1A1SMN1; SMN2 | |
| SCHEMBL17485268 | 0.84 | MAPT (0.63) | MAPTPKMSLC6A3ALDH1A1SMN1; SMN2 | |
| SCHEMBL17485280 | 0.83 | MAPT (0.54) | MAPTPKMALDH1A1 | |
| SCHEMBL17485234 | 0.82 | PDE4B (0.60) | MAPTPKMKDM4EALDH1A1 | |
| SCHEMBL17474501 | 0.82 | PDE4B (0.60) | MAPTPKMKDM4EALDH1A1 | |
| SCHEMBL17485185 | 0.82 | MAPT (0.58) | MAPTPKMSLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| US-9546151-B2 | VMAT inhibitory compounds | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546151-B2 | VMAT inhibitory compounds | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160031852-A1 | VMAT INHIBITORY COMPOUNDS | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2016-02-04 | — | — | US | disclosed |
| US-20160031852-A1 | VMAT INHIBITORY COMPOUNDS | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | MAPT 259/4885PKM 809/4885SLC6A4 6/4885 |
| US-20160031852-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | MAPT 259/4885PKM 809/4885SLC6A4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.